Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd.

SZSE:300313 Stock Report

Market Cap: CN¥2.1b

Xinjiang Tianshan Animal Husbandry Bio-engineering Past Earnings Performance

Past criteria checks 0/6

Xinjiang Tianshan Animal Husbandry Bio-engineering has been growing earnings at an average annual rate of 5.2%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been declining at an average rate of 14.2% per year.

Key information

5.2%

Earnings growth rate

4.7%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate-14.2%
Return on equity-157.4%
Net Margin-34.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. (SZSE:300313) Investors Are Less Pessimistic Than Expected

Oct 02
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. (SZSE:300313) Investors Are Less Pessimistic Than Expected

Some Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. (SZSE:300313) Shareholders Look For Exit As Shares Take 26% Pounding

Jun 27
Some Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. (SZSE:300313) Shareholders Look For Exit As Shares Take 26% Pounding

Some Confidence Is Lacking In Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. (SZSE:300313) As Shares Slide 35%

Apr 19
Some Confidence Is Lacking In Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. (SZSE:300313) As Shares Slide 35%

What Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd.'s (SZSE:300313) 44% Share Price Gain Is Not Telling You

Mar 05
What Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd.'s (SZSE:300313) 44% Share Price Gain Is Not Telling You

Revenue & Expenses Breakdown

How Xinjiang Tianshan Animal Husbandry Bio-engineering makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300313 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24148-51312
30 Jun 24138-37291
31 Mar 24132-25282
31 Dec 23137-22272
30 Sep 23125-17211
30 Jun 2394-33191
31 Mar 2387-31180
01 Jan 2376-32181
30 Sep 2293-34212
30 Jun 2296-29222
31 Mar 22110-30232
01 Jan 22108-27272
30 Sep 2191-14250
30 Jun 21942280
31 Mar 211357300
31 Dec 201634301
30 Sep 20282-36482
30 Jun 20277-50522
31 Mar 20239-57552
31 Dec 19229-61582
30 Sep 19116-51512
30 Jun 19121-104511
31 Mar 19107-1,949531
31 Dec 18105-1,946511
30 Sep 18125-1,919492
30 Jun 18162-1,855492
31 Mar 181927492
31 Dec 171957512
30 Sep 17181-78731
30 Jun 17245-108840
31 Mar 17272-128900
31 Dec 16375-140970
30 Sep 16419-79880
30 Jun 16407-55820
31 Mar 16362-44800
31 Dec 15247-36740
30 Sep 15214-19640
30 Jun 15129-13580
31 Mar 15125-6520
31 Dec 141222460
30 Sep 14958370
30 Jun 148810360
31 Mar 148412330
31 Dec 138310340

Quality Earnings: 300313 is currently unprofitable.

Growing Profit Margin: 300313 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300313 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.2% per year.

Accelerating Growth: Unable to compare 300313's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 300313 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).


Return on Equity

High ROE: 300313 has a negative Return on Equity (-157.42%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 23:52
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jinhou ZhaoSWS Research Co., Ltd.